WCLC Sept 2021 | Pralsetinib in Chinese patients with advanced RET fusion+ NSCLC

Qing Zhou, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, describes a cohort analysis presented at the World Conference on Lung Cancer (WCLC) 2021, from the global Phase I/II ARROW study (NCT03037385) of pralsetinib, a highly potent and selective RET kinase inhibitor. The analysis demonstrates that first line pralsetinib therapy induces rapid, durable tumor responses and a well-tolerated safety profile in Chinese patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC). Dr Zhou proposes that pralsetinib represents a promising first line treatment option for Chinese patients with RET-fusion driven advanced NSCLC. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.